5-Azacytidine Reprograms Colorectal Cancer Cells Toward Senolytic Vulnerability and Enhanced T-Cell-Mediated Cytotoxicity
4 affiliations
- 1Department of Genetics and Life Sciences, Sirius University of Science and Technology, 354340 Sirius, Russia
- 2Institute of Cytology RAS, 194064 St. Petersburg, Russia
- 3French National Institute of Health and Medical Research, Joint Research Unit 1231, University of Burgundy, 21078 Dijon, France
- 4Institute of Urology and Clinical Oncology, Bashkir State Medical University, 450008 Ufa, Russia
Abstract
Aberrant DNA methylation is a hallmark of colorectal cancer (CRC) and represents a potential therapeutic target. DNA methyltransferase inhibitors can induce sustained transcriptional and phenotypic reprogramming of tumor cells; however, the therapeutic vulnerabilities created by this reprogramming are not completely understood. Here, we investigated the effects of 5-azacitidine (5-AZA) in the human CRC cell lines HT-29 and DLD-1 and assessed whether epigenetic priming could subsequently be exploited using senolytic or immunotherapeutic approaches. Treatment with 5-AZA reduced cell proliferation and induced a senescent phenotype accompanied by increased expression of the cyclin-dependent kinase inhibitors CDKN1A and CDKN2B and anti-apoptotic BCL-2 family proteins as well as p16 expression on protein level. These changes were most pronounced in HT-29 cells. Pretreatment with 5-AZA sensitized HT-29 cells to navitoclax, a broad-spectrum BH3 mimetic, whereas the selective BCL-2 inhibitor venetoclax was less effective. In DLD-1 cells, both the senescent phenotype and sensitization to navitoclax were less pronounced, indicating that the response to epigenetic priming is dependent on tumor-cell context. By contrast, in an in vitro immunotherapy model using DLD-1 tumor cells, lymphocytes and a bispecific CD19 × CD3 T-cell engager (BiTE), pretreatment of tumor cells with 5-AZA enhanced T-cell-mediated cytotoxicity and increased IFN-γ production. Thus, 5-AZA induces therapeutically relevant reprogramming of CRC cells, sensitizing them to navitoclax while simultaneously increasing their susceptibility to T-cell-mediated elimination. These findings provide a rationale for further investigation of sequential treatment strategies combining epigenetic priming with senolytic or immunotherapeutic approaches.
Related
- Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition
- Primary cilia disruption reprograms extracellular vesicle signaling in endothelial dysfunction and cardiovascular disease
- Transcription factor Fra-1 reprograms androgen receptor chromatin binding and super-enhancers in osteoblast differentiation
- Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer
- Acute degron-mediated RUNX1 loss reprograms enhancer activity associated with epithelial destabilization and initiation of cancer hallmarks
BibTeX
@article{lisitsa20265azacytidine,
title = {{5-Azacytidine Reprograms Colorectal Cancer Cells Toward Senolytic Vulnerability and Enhanced T-Cell-Mediated Cytotoxicity}},
author = {Darya A. Lisitsa and Ekaterina D. Kolosova and Natalia A. Budkina and Viktoria M. Petrova and Oleg N. Demidov and Daria A. Bogdanova},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210250},
url = {https://www.mdpi.com/1422-0067/27/22/10250},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - 5-Azacytidine Reprograms Colorectal Cancer Cells Toward Senolytic Vulnerability and Enhanced T-Cell-Mediated Cytotoxicity
AU - Darya A. Lisitsa
AU - Ekaterina D. Kolosova
AU - Natalia A. Budkina
AU - Viktoria M. Petrova
AU - Oleg N. Demidov
AU - Daria A. Bogdanova
PY - 2026
DA - 2026/11/15
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210250
UR - https://www.mdpi.com/1422-0067/27/22/10250
AB - Aberrant DNA methylation is a hallmark of colorectal cancer (CRC) and represents a potential therapeutic target. DNA methyltransferase inhibitors can induce sustained transcriptional and phenotypic reprogramming of tumor cells; however, the therapeutic vulnerabilities created by this reprogramming are not completely understood. Here, we investigated the effects of 5-azacitidine (5-AZA) in the human CRC cell lines HT-29 and DLD-1 and assessed whether epigenetic priming could subsequently be exploited using senolytic or immunotherapeutic approaches. Treatment with 5-AZA reduced cell proliferation and induced a senescent phenotype accompanied by increased expression of the cyclin-dependent kinase inhibitors CDKN1A and CDKN2B and anti-apoptotic BCL-2 family proteins as well as p16 expression on protein level. These changes were most pronounced in HT-29 cells. Pretreatment with 5-AZA sensitized HT-29 cells to navitoclax, a broad-spectrum BH3 mimetic, whereas the selective BCL-2 inhibitor venetoclax was less effective. In DLD-1 cells, both the senescent phenotype and sensitization to navitoclax were less pronounced, indicating that the response to epigenetic priming is dependent on tumor-cell context. By contrast, in an in vitro immunotherapy model using DLD-1 tumor cells, lymphocytes and a bispecific CD19 × CD3 T-cell engager (BiTE), pretreatment of tumor cells with 5-AZA enhanced T-cell-mediated cytotoxicity and increased IFN-γ production. Thus, 5-AZA induces therapeutically relevant reprogramming of CRC cells, sensitizing them to navitoclax while simultaneously increasing their susceptibility to T-cell-mediated elimination. These findings provide a rationale for further investigation of sequential treatment strategies combining epigenetic priming with senolytic or immunotherapeutic approaches.
SN - 1422-0067
ER -